International network for natural sciences – research journal
  • mendeley icon
  • linkedin icon
  • google plus icon
  • twitter icon
  • google scholar icon
  • facebook icon

Microbial association related to infectious diseases

By: Qurrat ul ain Rana, Ismail Jali, Wasim Sajjad, Anwar Sheed Khan, Sajid Ali, Ghufranud Din, Muhammad Irfan

Key Words: Probiotics, CD4+ T cells, Pathogenicity, Lipopolysaccharide, phagocytosis, Lysosome.

Int. J. Biosci. 16(5), 245-255, May 2020.


Certification: ijb 2020 0019 [Generate Certificate]


The microbiotaarea differing network of microorganisms that colonize the human body. In spite of noteworthy advances in treating irresistible illnesses around the world, the rate of dying and morbidnessrelated tomicrobiota disease rests remarkably high and signifies a basic logical and worldwide health challenge. Presentapproaches to conflict these irresistible operators contain a mix of minor molecule drugs, vaccines, disease-explicit mediations, and expanded cleanliness guidelines. The mammalian resistant framework assumes a basic job in keeping up homeostasis with inhabitant microbial networks, along these lines guaranteeing that the mutualistic idea of the host-microbial relationship is preserved.At this point, we designate how the human microflora impacts vulnerability irresistible ailments, we survey advances in our comprehension of the cooperations between inhabitant organisms and the insusceptible framework and the ramifications of these discoveries for human wellbeing.

| Views 39 |

| Views 39 |

Microbial association related to infectious diseases

Bassis CMErb-Downward JRDickson RPFreeman CMSchmidt TMYoung VBBeck JMCurtis JLHuffnagle GB. 2015. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 6(2), 1-15.

Becattini S, Taur Y, Pamer EG. 2016. Antibiotic-induced changes in the intestinal microbiota and disease. Trends in molecular medicine 22, 458-478.

Bezkorovainy A. 2001. Probiotics: determinants of survival and growth in the gut. The American journal of clinical nutrition 73, 399s-405s.

Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. 2017. Regulation of inflammation by microbiota interactions with the host. Nature immunology 18, 851-860.

Buffie CG, Pamer EG. 2013. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology 13, 790-801.

Cases C. 1998. Isolation of avian influenza A (H5N1) viruses from humans—Hong Kong, May-December 1997. JAMA 46(50), 1204-7.

Cohen ML. 2000. Changing patterns of infectious disease. Nature 406, 762-767.

Collins AM. 2014. Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield. JoVE (Journal of Visualized Experiments):e4345 Control CfD, Prevention (2000) Guidelines for surveillance, prevention, and control of West Nile virus infection–United States. MMWR. Morbidity and mortality weekly report 49, 25.

Crosby AW. 2003. America’s forgotten pandemic: the influenza of 1918. Cambridge University Press.

Cullen CM. 2020. Emerging Priorities for Microbiome Research. Frontiers in Microbiology 11, 136.

Di Paola M. 2017. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Scientific reports 7, 1-12.

Dickson RP. 2015a. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Annals of the American Thoracic Society 12, 821-830.

Dickson RP. 2017. Bacterial topography of the healthy human lower respiratory tract. mBIO 8(1),

Dickson RP, Erb-Downward JR, Huffnagle GB. 2015b. Homeostasis and its disruption in the lung microbiome. American Journal of Physiology-Lung Cellular and Molecular Physiology 309, L1047-L1055.

Dickson RP. 2014 Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. Journal of clinical microbiology 52, 3605-3613.

Doerflinger SY, Throop AL, Herbst-Kralovetz MM. 2014. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. The Journal of infectious diseases 209, 1989-1999.

Domingue JC, Drewes JL, Merlo CA, Housseau F, Sears CL. 2020. Host responses to mucosal biofilms in the lung and gut. Mucosal Immunology 1-10.

FigueroaGonzález I, Quijano G, Ramírez G, CruzGuerrero A. 2011. Probiotics and prebiotics—perspectives and challenges. Journal of the Science of Food and Agriculture 91, 1341-1348.

Foxx-Orenstein AE, Chey WD. 2012. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. The American Journal of Gastroenterology Supplements 1, 41–46.

Francino M. 2016. Antibiotics and human gut microbiome: dysbioses and accumulation of resistances. Frontier Microbiology 12(6), 1543.

Gareau MG, Sherman PM, Walker WA. 2010. Probiotics and the gut microbiota in intestinal health and disease. Nature reviews Gastroenterology & hepatology 7(9), 503-14.

Garrett L. 1994. The coming plague: newly emerging diseases in a world out of balance. Macmillan

Gibson GR, Probert HM, Van Loo J, Rastall RA, Roberfroid MB. 2004. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutrition research reviews 17, 259-275.

Hearps A. 2017. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal immunology 10, 1480-1490.

Huttenhower C. 2012. Structure, function and diversity of the healthy human microbiome. nature 486, 207-214.

Istúriz RE, Gubler DJ, del Castillo JB. 2000. Dengue and dengue hemorrhagic fever in Latin America and the Caribbean. Infectious Disease Clinics

14, 121-140.

Kass EH. 1987. History of the specialty of infectious diseases in the United States. Annals of internal medicine 106, 745-756.

Keller MJ. 2016. Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV‐Infected and Uninfected Women. American Journal of Reproductive Immunology 75, 631-642.

Łaniewski P. 2018 Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Scientific reports 8, 1-13.

Lennard K. 2018. Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females. Infection and immunity 86(1), e00410-17.

Li J, Convertino M.2019. Optimal microbiome networks: macroecology and criticality. Entropy 21, 506.

Lim B, Zimmermann M, Barry NA, Goodman AL. 2017. Engineered regulatory systems modulate gene expression of human commensals in the gut. Cell 169, 547-558. e515

Martin Jr HL. 1999. Vaginal lactobacilli, microbial

flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. Journal of Infectious Diseases 180, 1863-1868.

Martín R. 2015. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiology 15, 67.

Masson L. 2014. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sexually transmitted infections 90, 580-587.

McClelland RS. 2018. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. The Lancet infectious diseases 18, 554-564.

Mirzaei MK, Maurice CF. 2017. Ménage à trois in the human gut: interactions between host, bacteria and phages. Nature Reviews Microbiology 15, 397-408.

Mojgani N, Shahali Y, Dadar M. 2020. Immune modulatory capacity of probiotic lactic acid bacteria and applications in vaccine development. Beneficial Microbes 0, 1-14.

Mukherjee S, Joardar N, Sengupta S, Babu SPS. 2018. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. The Journal of nutritional biochemistry 61, 111-128.

Murdock BJ. 2012. Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infection and immunity 80, 1424-1436.

Novello A. 2000. Update: West Nile Virus activity-Eastern United States, 2000. Morbidity and Mortality Weekly Report 49, 1044-1047.

World Health Organization. 2000. The world health report 2000: health systems: improving performance. World Health Organization.

Pace BT, Lackner AA, Porter E, Pahar B. 2017. The role of defensins in HIV pathogenesis. Mediators of inflammation 2017.

Pandey KR, Naik SR, Vakil BV. 2015. Probiotics, prebiotics and synbiotics-a review. Journal of food science and technology 52, 7577-7587.

Pecora DV. 1963. A comparison of transtracheal aspiration with other methods of determining the bacterial flora of the lower respiratory tract. New England Journal of Medicine 269, 664-666.

Pinner RW. 1996. Trends in infectious diseases mortality in the United States. The Journal of the American Medical Association. 275(3), 189-193.

Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nature reviews immunology 9, 313-323.

Segal LN. 2016. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nature microbiology 1-16031.

Sewankambo N. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. The Lancet 350, 546-550.

Shenoy MK. 2017. Immune response and mortality risk relate to distinct lung microbiomes in patients with HIV and pneumonia. American journal of respiratory and critical care medicine 195, 104-114.

Sibley CD. 2011. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PloS ONE 6(7).

Van Nood E. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 368, 407-415.

Waldman AJ, Balskus EP. 2018. The human microbiota, infectious disease, and global health: challenges and opportunities. ACS infectious diseases 4, 14-26.

Wallace BD, Redinbo MR. 2013. The human microbiome is a source of therapeutic drug targets. Current opinion in chemical biology 17, 379-384.

Wallace BD. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835.

Webster RG. 1998. Influenza: an emerging disease. Emerging infectious diseases 4(3), 436–441.

Wessels JM. 2017. Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus. PLoS One 12, 11.

Wilson J, Schurr M, LeBlanc C, Ramamurthy R, Buchanan K, Nickerson C. 2002. Mechanisms of bacterial pathogenicity. Postgraduate medical journal 78, 216-224.

Young VB. 2017. The role of the microbiome in human health and disease: an introduction for clinicians. British Medical Journal 15, 356-j831.

Zacho J, Benfield T, Tybjærg-Hansen A, Nordestgaard BG. 2016. Increased baseline C-reactive protein concentrations are associated with increased risk of infections: results from 2 large Danish population cohorts. Clinical chemistry 62, 335-342.

Qurrat ul ain Rana, Ismail Jali, Wasim Sajjad, Anwar Sheed Khan, Sajid Ali, Ghufranud Din, Muhammad Irfan.
Microbial association related to infectious diseases.
Int. J. Biosci. 16(5), 245-255, May 2020.
Copyright © 2020
By Authors and International Network for
Natural Sciences (INNSPUB)
innspub logo
english language editing
    Publish Your Article
    Submit Your Article
Email Update